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Abstract
Congenital heart disease (CHD) is the most frequent birth defect, affecting 0.8% of live births1.
Many cases occur sporadically and impair reproductive fitness, suggesting a role for de novo
mutations. By analysis of exome sequencing of parent-offspring trios, we compared the incidence
of de novo mutations in 362 severe CHD cases and 264 controls. CHD cases showed a significant
excess of protein-altering de novo mutations in genes expressed in the developing heart, with an
odds ratio of 7.5 for damaging mutations. Similar odds ratios were seen across major classes of
severe CHD. We found a marked excess of de novo mutations in genes involved in production,
removal or reading of H3K4 methylation (H3K4me), or ubiquitination of H2BK120, which is
required for H3K4 methylation2–4. There were also two de novo mutations in SMAD2; SMAD2
signaling in the embryonic left-right organizer induces demethylation of H3K27me5. H3K4me and
H3K27me mark `poised' promoters and enhancers that regulate expression of key developmental
genes6. These findings implicate de novo point mutations in several hundred genes that
collectively contribute to ~10% of severe CHD.
From more than 5000 probands enrolled in the Congenital Heart Disease Genetic Network
Study of the National Heart Lung and Blood Institute Pediatric Cardiac Genomics
Consortium7, we selected 362 parent-offspring trios comprising a child (proband) with
severe CHD and no first-degree relative with identified structural heart disease. Probands
with an established genetic diagnosis were excluded. There were 154 probands with
conotruncal defects, 132 with left ventricular obstruction, 70 with heterotaxy and six with
other diagnoses (Supplementary Table 1).
Genomic DNA samples from trios underwent exome sequencing (see Methods)8. Targeted
bases in each sample were sequenced a mean of 107 times by independent reads with 96.0%
read eight or more times. In parallel, 264 trios comprising unaffected siblings of autism
cases and their unaffected parents (Supplementary Table 1) were sequenced in the same
facility using the same protocol and were analyzed as a control group9 (Supplementary
Table 2, Supplementary Figure 1). Family relationships were confirmed from sequence data
in all trios.
High probability de novo variants in probands were identified using a Bayesian quality score
(QS; see Methods). Sanger sequencing of 181 putative de novo mutations across the QS
spectrum demonstrated strong correlation of confirmation with QS (R2 = 0.89), with 100%
confirmation of 90 calls with QS > 50 (Supplementary Table 3, Supplementary Figure 2).
Consequently, de novo mutation calls with QS ≥ 50 were included in the study; this set is
estimated to include 90% of mutations with QS > 0, with ~100% specificity; 90% of these
have the maximum QS of 100 (Supplementary Figure 3). Sensitivity is further diminished
by ~5% due to bases with very low read coverage. We found 0.88 de novo mutations per
subject in CHD cases and 0.85 in controls. These mutation rates (1.34 and 1.29 × 10−8 per
targeted base) are not significantly different (P = 0.63, binomial test) and are similar to prior
estimates10. The set of de novo mutations is shown in Supplementary Table 4.
CHD cases and controls had very similar maternal and paternal ages, which had a small
impact on the mutation rate (Supplementary Figure 4). We found no significant effect of
geographic ancestry on the mutation rate (Supplementary Figure 5). The number of de novo
mutations per subject closely approximated the Poisson distribution, providing no evidence
for mutation clustering (Supplementary Figure 6).
Genes contributing to CHD should be expressed in the developing heart/anlagen or tissues
that provide developmental cues. We used RNA sequencing of mouse heart at embryonic
day (e)14.5 (Supplementary Methods) to partition 16,676 genes with identified human-
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mouse orthologs into the top quartile of expression (4,169 genes with high heart expression,
HHE; threshold >40 reads per million (rpm) mapped reads) and the bottom 75% (12,507
with lower heart expression, LHE). The HHE set included regulatory genes known to be
expressed at this stage such as Gata4, Nkx2.5, and Tbx5.
We found a significant increase in the rate of protein-altering de novo mutations in HHE
genes in patients with CHD compared to controls (P = 0.003, binomial test, OR = 2.53,
Table 1). Because it is unlikely that all such de novo mutations alter protein function, we
enriched for deleterious de novo mutations, first removing missense mutations at weakly
conserved positions among vertebrate orthologs (two or more species with substitutions,
median seven), then removing missense mutations at highly conserved positions (zero or one
species with substitution; 72% with 0), leaving only damaging mutations (premature
termination, splice site and frameshift). This produced successive increases in the OR's to
3.67 and 7.50, with significant differences between cases and controls in each group (Table
1a, Figure 1a). The rise in odds ratio with increasing stringency was significant (P = 0.001,
logistic model regression). Other predictors of deleterious mutations, such as Polyphen2,
yielded similar results (probably deleterious missense mutations + damaging mutations, P =
0.0007, binomial test). Similar results were found when genes were partitioned across a
range of expression thresholds in the developing heart (Supplementary Table 5) and also
when analyses used heart RNA expression from e9.5 (Supplementary Table 6). In contrast,
there was no significant difference in mutation frequency in CHD cases vs. controls among
LHE genes, with OR's near or < 1 in all comparisons (Supplementary Table 7, Figure 1a).
Analysis comparing the presence or absence of de novo mutations in each case and control
yielded similar results (Supplementary Table 8 and Supplementary Figure 7). Examination
of subjects with left ventricular obstruction, conotruncal defects, and heterotaxy
demonstrated similarly increased OR's for each group (Supplementary Table 9).
Comparison of de novo mutation frequencies in HHE genes vs. LHE genes in the CHD
cohort also revealed a significantly greater rate in HHE genes, again with OR increasing
with increasingly stringent filters (Supplementary Table 7, Figure 1b). In contrast, controls
showed no significant difference in mutation frequencies in HHE vs. LHE, again with all
odds ratios near or < 1 (Supplementary Table 7, Figure 1b).
Strikingly, examination of genes mutated in the CHD set revealed eight involved in
production, removal or reading of methylation of histone H3, lysine 4 (H3K4me).
Interestingly, three genes in this pathway (MLL2, KDM6A, CHD7) have previously been
implicated in severe CHD11,12. In Gene Ontology (GO) analysis (http://
david.abcc.ncifcrf.gov/) of the 249 protein-altering de novo mutations in CHD probands, the
H3K4me pathway was the only gene set with significant enrichment (P = 4 × 10−7, modified
Fisher exact test, P = 4 × 10−4 after Bonferroni correction; see Methods). The number of
mutations in this gene set expected by chance was one and controls showed none.
H3K4me is an activating mark found in promoters/enhancers of key developmental genes6.
Early in development `poised' promoters/enhancers have both activating H3K4me marks
and inactivating H3K27me marks; these promoters/enhancers and their target genes are
selectively activated by modification of these marks in different lineages. Mutations in these
genes (Table 2, Figure 2) included 27% of the damaging mutations in the HHE gene set.
Mutated genes included MLL2 (frameshift mutation) and WDR5 (missense), components of
the MLL2 H3K4 N-methyl transferase complex2; KDM5A (missense) and KDM5B (splice
donor), both H3K4 demethylases3; CHD7 (premature termination), an ATP-dependent
helicase that binds H3K4me sites12. There were also de novo mutations in RNF20
(premature termination) and UBE2B (missense), components of a histone H2BK120
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ubiquitination complex and in USP44 (missense), encoding an H2B deubiquitinase4.
Ubiquitination at H2BK120 is required for H3K4 methylation2.
Interestingly, SMAD2 is mutated twice (splice site, conserved missense) a finding unlikely
to occur by chance (P = 0.015, Monte Carlo simulation) (Table 2). SMAD2 is
asymmetrically phosphorylated downstream of NODAL signaling in the embryonic left-
right organizer, resulting in SMAD2 binding to chromatin, recruitment of JMJD3, and
demethylation of H3K27me, enabling transcriptional activation at poised sites5. Additional
genes of note (Table 2) include SUV420H1 (missense), encoding a histone H4 methylase;
MED20 (splice site), a component of the mediator complex; HUWE1 (missense), a ubiquitin
ligase targeting histones and TP53; CUL3 (frameshift), a scaffold for assembly of many
RING ubiquitin ligases8; NUB1 (missense), which inhibits NEDD8, a cofactor for cullin-
based ubiquitin ligases. Lastly, NAA15, an N-acetyltransferase13, had two damaging
mutations, unlikely a chance event (P = 0.01, Monte Carlo simulation). Among the 17 above
genes, ten have no damaging variants and seven have 1–5 among >9500 exomes in NHLBI
ESP, 1000 genomes and Yale exome databases.
Phenotypes of the eight patients with de novo mutations in the H3K4me pathway revealed
diverse cardiac phenotypes (Table 2, Supplementary Table 10). Other structural,
neurodevelopmental and growth abnormalities were common. Additionally, consistent with
a role in left-right axis determination5, both patients with SMAD2 mutations had
dextrocardia with unbalanced complete AV canal and pulmonary stenosis. For other genes
mutated more than once (e.g., NAA15), probands had dissimilar cardiac phenotypes
(Supplementary Table 11).
Before initiating exome sequencing, we defined a set of 277 candidate CHD genes
(Supplementary Table 12) from human and model system studies. There were 13 CHD
probands with de novo mutations in these genes (Table 2, Supplementary Table 13), more
than expected by chance (P = 7 × 10−4, Monte Carlo simulation) or in controls (n= 1, P =
0.006, binomial test). This set included several genes known to cause Mendelian CHD,
however affected subjects lacked cardinal disease manifestations or had atypical cardiac
features. For example, the patient with CHD7 mutation had none of the major criteria
(coloboma, choanal atresia or hypoplastic semi-circular canals) for CHARGE syndrome12.
Similarly, the patient with MLL2 mutation was not prospectively diagnosed with Kabuki
syndrome, however re-evaluation at age 2 after sequencing identified characteristic facial
features. Additionally, a patient with an NF1 mutation had a complex conotruncal defect, an
unusual finding in neurofibromatosis. These findings support variable expressivity and a
broader phenotypic spectrum resulting from mutations at known disease loci. Other genes of
interest in this set included RAB10 and BCL9, identified as candidates by rare de novo
CNVs14.
Our results implicate de novo point/indel mutations that by chance occur in genes required
for normal heart development in the pathogenesis of diverse CHDs. Consistent with this
inference, genes with damaging and conserved missense mutations in CHD probands
showed higher expression in e14.5 mouse heart compared to controls (Supplementary Figure
8; median 45 vs. 16 rpm, P = 5 × 10−4, Wilcoxon signed-rank test), while expression of
genes with silent mutations show no significant difference (median 21 vs. 19 rpm, P = 0.7,
Wilcoxon signed-rank test). Expression at e9.5 shows similar results (Supplementary Figure
8). The increased mutation burden of HHE genes in cases is not due to a higher intrinsic
mutation rate of these genes because the rate is significantly higher than in controls;
moreover, there is no significant difference in mutation rate between HHE and LHE genes in
controls. Further, partitioning genes into analogous high and low expression groups for four
control adult tissues (brain, heart, liver and lung) showed no significant differences in
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mutation burden between cases and controls or between high and low expression groups
(Supplementary Figure 9).
From the increased fraction of patients with protein-altering mutations in HHE genes in
CHD patients (0.22) vs. controls (0.12), we estimate that such mutations play a role in about
10% of these patients (95% confidence interval 5%–15%). This could be somewhat
underestimated, since mutation detection is incomplete, analysis is limited to genes with
identified mouse orthologs, and the HHE set may not include all trait loci. Similarly, the
observed ORs may be somewhat underestimated since not all mutations in cases are likely to
confer risk.
These findings establish that mutations in many genes in the H3K4me-H3K27me pathway
disrupt cardiac development and are consistent with prior evidence implicating these
chromatin marks in regulating key developmental genes6, including those involved in
cardiac development15,16. Targeted sequencing in larger CHD cohorts will enable
assessment of the role of each individual gene in this pathway. These findings imply dosage
sensitivity for these chromatin marks in CHD, similar to recent findings implicating
haploinsufficiency for chromatin modifying/remodeling genes in diverse cancers17,18.
Investigation of the consequences of these mutations on specific enhancers/promoters and
the genes they regulate will likely provide further insight into the CHD pathogenesis.
The demonstration that point/indel mutations contribute to ~10% of CHD patients and the
finding that six genes were mutated twice (Supplementary Table 11) enables an estimate of
the size of the gene set that contributes to these CHDs (see Methods). The point-wise
estimate is 401 genes (95% confidence interval 197–813), indicating that many more CHD-
related genes and pathways remain to be discovered.
Exome sequencing of probands with autism have revealed broadly similar results: de novo
mutations in a large set of genes occur in a significant fraction of patients, with relatively
high OR's for damaging mutations in genes expressed in the brain9,19–21. Most interestingly,
CHD8, which like CHD7 reads H3K4me marks, is frequently mutated in autism22, raising
the question of whether the H3K4me pathway may play a role in many congenital diseases.
Among 249 protein-altering de novo mutations in CHD (Supplementary Table 4) and 570
such mutations in autism9,19,20,23, there were two genes, CUL3 and NCKAP1, with
damaging mutations in both CHD and autism and none in controls (P = 0.001, Monte Carlo
simulation), and several others with mutations in both (e.g., SUV40H1 and CHD7).
Similarly, rare copy number variants at 22q11.2, 1q21, and 16p11 are found in patients with
autism, CHD or both diseases24–26. These observations suggest variable expressivity of
mutations in key developmental genes. Identification of the complete set of these
developmental genes and the full spectrum of the resulting phenotypes will likely be
important for patient care and genetic counseling.
Our findings do not resolve the pathogenesis of most CHD cases. Rare and de novo copy
number variants appear to account for a small fraction14,27; rare or common transmitted
variants are expected to also make significant contributions. Additionally, considering the
role of H3K4me and H3K27me marks in promoter/enhancer regulation, non-coding
mutations cannot be dismissed. Lastly, evidence of dosage sensitivity of many chromatin-
modifying genes raises the possibility that environmental perturbations of these pathways in
critical developmental windows might phenocopy the effects of these mutations.
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METHODS
Patient cohorts
Probands with or without parents were recruited from 9 centers in the United States and the
United Kingdom into the Congenital Heart Disease Genetic Network Study of the Pediatric
Cardiac Genomics Consortium (CHD Genes: NCT01196182)7. The protocol was approved
by the Institutional Review Boards of Boston Children's Hospital, Brigham and Women's
Hospital, Great Ormond St. Hospital, Children's Hospital of Los Angeles, Children's
Hospital of Philadelphia, Columbia University Medical Center, Icahn School of Medicine
and Mt. Sinai, Rochester School of Medicine and Dentistry, Steven and Alexandra Cohen
Children's Medical Center of New York, and Yale School of Medicine. Written informed
consent was obtained from each participating subject or their parent/guardian. Probands
were selected for severe congenital heart disease (excluding isolated VSDs, ASDs, PDAs or
PSs), availability of both parents, and absence of any CHD in first-degree relatives. Cardiac
diagnoses were obtained from review of echocardiogram, catheterization and operative
reports; extracardiac findings were extracted from medical records. Controls were from 264
previously studied quartets that included one offspring with autism, an unaffected sibling
and unaffected parents, all recruited with written informed consent by the Simons
Foundation Autism Research Initiative28. Parents and their unaffected sibling from this
cohort were analyzed in the current study.
Exome sequencing
Trios were sequenced at the Yale Center for Genome Analysis following the same protocol.
Genomic DNA from venous blood was captured with the NimbleGen v2.0 exome capture
reagent (Roche) and sequenced (Illumina HiSeq 2000, 75 base paired-end reads). Reads
were mapped to the reference genome using Eland. SNV and indel calls were assigned
quality scores (QS) using SAMtools8 and annotated for novelty using dbSNP, build 135,
1000 genomes, May 2011 release and the Yale Exome Database, for impact on encoded
proteins, and conservation of variant position.
Identification and confirmation of de novo mutations
Heterozygous SNVs and indels in the proband that showed QS ≥ 60 and 600, respectively,
and rare non-reference calls in both parents were selected. Read plots of all putative indels
were visually inspected in trio members to eliminate false calls. A Bayesian algorithm was
used to assist de novo mutation calls. Elements included probability of the proband being
heterozygous at the test position; probability that parents are homozygous for the reference
allele, given frequency of reference and non-reference reads and probability of
heterozygosity in offspring; probability that a variant is de novo given its population
frequency. Resulting QSs scaled from 0 to 100. Their correlation with bona fide de novo
mutations was determined by Sanger sequencing of PCR amplicons harboring 181 putative
mutations distributed across the QS spectrum. Additionally, all six de novo indels with QS >
50 in the HHE gene set were tested and confirmed by Sanger sequencing.
RNA sequencing and analysis
Hearts from e14.5 mouse embryos (strain 129SvEv) were isolated, rinsed, and immersed in
RNALater. Left and right atria, left ventricle (with interventricular septum, aortic and mitral
valves), and right ventricle (with pulmonary and tricuspid valves) were dissected. Chamber-
specific RNAs were extracted and pooled from 5 embryos, selected with oligo-dT, copied
into double stranded DNA, and ligated to adaptors. 150–250 bp fragments were isolated
after acrylamide gel electrophoresis, amplified and sequenced (Illumina HiSeq2000), with >
40 million paired-end 50 base reads per library as previously described29. Reads were
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aligned to the mouse genome (mm9)30, and reads per gene per million mapped reads (rpm)
was determined. The average of rpm of each gene from each chamber was used as the
measure of heart expression. RNA from atria, ventricle and truncus/outflow tract at e9.5 was
prepared, sequenced and analyzed by an analogous approach. RNA sequencing of control
human adult tissues- lung, liver, heart and brain- from the Illumina Human Body Map
(http://www.ebi.ac.uk/arrayexpress/browse.html?keywords=E-MTAB-513) was similarly
performed and analyzed as reads per gene per million reads per kb of transcript.
Principal component analysis
The EIGENSTRAT program was used to compare SNP genotypes of probands and
individuals of known ancestry in HapMap3 (http://hapmap.ncbi.nlm.nih.gov/). SNPs with
MAF >5% without significant linkage disequilibrium with other SNPs were analyzed. The
results of analysis correctly distinguished ancestry groups in HapMap3 samples; ancestries
of CHD subjects were assigned accordingly.
Statistical analyses
The significance of mutation frequency differences between groups was tested with two-
tailed binomial exact tests; two-tailed Fisher exact tests assessed differences in numbers of
patients with one or more de novo mutations; tests among 3 groups was by Chi-square
analysis. Gene expression at e14.5 of genes mutated in cases and controls was compared by
Wilcoxon signed-rank test. Correlation of mutation rate and parental age was tested by
Pearson's correlation. The expected number of genes with more than one de novo mutation
was determined by Monte Carlo simulation (108 iterations) specifying the total number of
protein-altering mutations and 21,000 genes of observed coding length. Analogous
approaches were used to determine probabilities of any gene having ≥ 2 damaging
mutations, ≥ 1 damaging and ≥ 1 mutation at a conserved position, and ≥ 13 genes mutated
in both CHD and autism. The fit to the Poisson distribution of the observed numbers of de
novo mutations per subject was assessed by Chi-square test.
Overrepresentation of de novo mutations in the H3K4me pathway and the presence of
significant enrichment of other gene pathways was tested via Gene Ontology (GO) analysis,
using a modified Fisher's exact test with Bonferroni correction as implemented in DAVID
(http://david.abcc.ncifcrf.gov/). Input was all genes with protein-altering de novo mutations
in CHD or control subjects, and all genes sequenced. The H3K4me gene set was: CHD8,
MLL3, SETD7, WHSC1L1, CDC73, WHSC1, SETD1A, MLL2, KDM5A, MLL4, MLL5,
UBE2B, ASH1L, SETD1B, MLL, LEO1, PAF1, KDM5C, CTR9, PRDM9, MEN1, CHD7,
RNF20, KDM1A, RNF40, SMYD3, KDM6A, KDM5B, USP44, WDR5. The expected
number of mutations in the H3K4me set was calculated from the fraction of the exome
coding region attributable to this gene set and the total number of de novo mutations.
Estimating number of genes in which de novo mutations contribute to CHD
We addressed this question using the `unseen species problem'9. We infer that the number of
probands with non-synonymous mutations in the HHE set (81) minus the expected number
(44; calculated from the number observed in controls), represents the number of subjects in
whom de novo mutations confer CHD risk (37; 10.0% of probands). The number of genes
with > 1 protein-altering de novo mutation (six) minus the most likely number expected by
chance (three) represents risk-associated genes with more than 1 mutation (three). The
number of risk-associated genes (C) is estimated as follows:
C = c/u + g2×d× (1-u)/u
c = number of observed risk-associated genes (34)
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c1 = number of genes mutated once (31)
d = total number of risk-associated mutations (37)
g = variation in effect size of individual de novo mutations (assumed to be 1, which
minimizes underestimation of set size)
u = 1 – c1/d (probability that newly added mutation hits a previously mutated gene)
C = 401
From 95% confidence intervals of the number of risk-associated events, the 95% confidence
interval for number of risk genes is calculated as 197–837.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrichment of non-synonymous de novo mutations in heart-expressed genes
a, Odds ratios (ORs), standard errors and P-values (two-tailed binomial exact test) are
shown comparing incidence of classes of de novo mutations in CHD cases versus controls
for genes in top 25% (red bars) and bottom 75% (blue bars) of expression at e14.5 in
developing heart. b, ORs for incidence of mutations in genes in top 25% versus bottom 75%
of expression in CHD cases (red bars) and controls (blue bars). `Damaging' denotes
premature termination, frameshift or splice site mutations; `Conserved MS' and `Noncons
MS' denote mutations at highly or poorly conserved positions, respectively. NS, not
significant.
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Figure 2. De novo mutations in the H3K4 and H3K27 methylation pathways
Nucleosome with histone octamer and DNA, with H3K4 methylation bound by CHD7,
H3K27 methylation and H2bK120 ubiquitination is shown. Genes mutated in CHD that
affect the production, removal and reading of these histone modifications are shown; genes
with damaging mutations are shown in red, those with missense mutations are shown in
blue. SMAD2 (2) indicates there are two patients with mutation in this gene. Genes whose
products are found together in a complex are enclosed in a box.
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Table 1
De novo mutations in genes with high expression in developing heart in CHD probands and controls
Mutations in genes in
top quartile of
expression at e14.5
Total # of de novo mutations De novo mutations/subject Odds Ratio
Cases:Cont (95%
Cl)†
P-value††
CHD 362 trios Controls 264 trios CHD 362 trios Controls 264 trios
Silent 21 21 0.06 0.08 N/A 0.35
Nonconserved Missense 27 17 0.07 0.06 1.59 (0.67–3.74) 0.76
Silent and Protein
Changing 102 53 0.28 0.20 N/A 0.05
All Protein Changing 81 32 0.22 0.12 2.53 (1.22–5.25) 0.003
Conserved Missense 39 13 0.11 0.05 3.00 (1.25–7.17) 0.01
Conserved and Damaging
Protein Altering 55 15 0.15 0.06 3.67 (1.60–8.42) 0.0004
Damaging 15 2 0.04 0.01 7.50 (1.52–36.95) 0.01
†
The odds ratio is the ratio of protein-altering to silent variants in cases divided by the corresponding ratio in controls
††P-values compare the number of variants in each category between cases and controls using a two-tailed binomial exact test
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Table 2
Genes of interest with de novo mutations in probands
ID Gene Mutation Dx Other Structural/Neuro/Ht-Wt
1-00596 MLL2 † p.Ser1722Argfs*9 LVO Y/Y/N
1-00853 WDR5 † p.Lys7Gln CTD N/Y/N
1-00534 CHD7 † p.Gln1599* CTD Y/Y/Y
1-00230 KDM5A † p.Arg1508Trp LVO N/N/Y
1-01965 KDM5B † p.IVS12+1 G>A LVO N/N/Y
1-01907 UBE2B † p.Arg8Thr CTD N/N/N
1-00075 RNF20 † p.Gln83* HTX Y/Y/Y
1-01260 USP44 † p.Glu71Asp LVO N/N/N
1-02020 SMAD2 †† p.IVS6+1 G>A HTX Y/N/N
1-02621 SMAD2 †† p.Trp244Cys HTX Y/na/N
1-01451 MED20 p.IVS2+2 T>C HTX N/Y/Y
1-01151 SUV420H1 p.Arg143Cys CTD N/Y/N
1-00750 HUWE1 p.Arg3219Cys LVO N/Y/N
1-00577 CUL3 p.Iso144Phefs*23 LVO Y/Y/N
1-00116 NUB1 p.Asp310His CTD Y/Y/Y
1-01828 DAPK3 p.Pro193Leu CTD N/N/na
1-03151 SUPT5H p.Glu451Asp LVO N/na/N
1-00455 NAA15 p.Lys335Lysfs*6 HTX Y/Y/N
1-00141 NAA15 p.Ser761* CTD N/na/Y
1-01138 USP34 p.Leu432Pro LVO N/na/N
1-00448 NF1 p.IVS6+4 delA CTD N/na/N
1-00802 PTCH1 p.Arg831Gln LVO N/na/N
1-02458 SOS1 p.Thr266Lys Other Y/Y/Y
1-02952 PITX2 p.Ala47Val LVO N/na/N
1-01913 RAB10 p.Asn112Ser Other N/na/N
1-00638 FBN2 p.Asp2191Asn CTD N/na/N
1-00197 BCL9 p.Met1395Lys LVO N/na/N
1-02598 LRP2 p.Gly4372Lys HTX N/na/N
†Gene involved in production, removal, reading of H3K4me
††Gene involved in removal of H3K27me; Dx, diagnosis; Other Structural/Neuro/Ht-Wt` denotes presence (Y) or absence (N) of other structural
abnormalities, impaired cognitive speech or motor development, and height and/or weight less than 5thpercentile for age, respectively; `na', data
not available. Further clinical details in Supplementary Tables 10 and 11. Associated syndromes: MLL2-Kabuki syndrome; CHD7- CHARGE
syndrome; CUL3- pseudohypoaldosteronism, type 2E.
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